Pipeline

ADC Program

Target

Indication

Platform

Discovery

Preclinical

P1 Dose
Escalation

P1 Proof of
Concept

P2 Pivotal Study

P3

Phase

Mersana’s innovative platforms are a highly efficient product engine that is building a robust discovery pipeline for us and our partners. Our ADCs in preclinical and clinical trials are first-in-class molecules that target multiple tumor types with high unmet medical need. We believe our platforms create an opportunity for our ADCs to demonstrate improved safety and efficacy relative to those developed using first-generation technology. Our lead asset, upifitamab rilsodotin (UpRi), is a first-in-class Dolaflexin ADC targeting NaPi2b that is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, and in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies. Mersana’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines.

ADC ProgramTargetIndicationPlatformDiscoveryPreclinicalP1P1P2P3
Clinical
Upifitamab
Rilsodotin (UpRi)*
NaPi2b
Platinum-Resistant Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
Platinum-Sensitive Ovarian Cancer Dolaflexin
XMT-1536*
NaPi2b
Recurrent Platinum-Sensitive Ovarian Cancer Maintenance Dolaflexin
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors Dolasynthen
XMT-2056
HER2
Multiple Solid Tumors Immunosynthen
XMT-2068
Tumor-Associated Antigen
Undisclosed Immunosynthen
XMT-2175
Tumor-Associated Antigen
Undisclosed Immunosynthen
Multiple Programs
Undisclosed
Undisclosed Immunosynthen Dolasynthen Dolaflexin
Platform Collaborations
Multiple
Multiple
Undisclosed Dolasynthen
Multiple**
Multiple
Undisclosed Dolaflexin
ASN004
5T4
Undisclosed Dolaflexin
DrugIndicationStage
Clinical
Upifitamab
Rilsodotin (UpRi)*
NaPi2b
Platinum-Resistant Ovarian Cancer DolaflexinP1
XMT-1536*
NaPi2b
Platinum-Sensitive Ovarian Cancer DolaflexinPreclinical
XMT-1536*
NaPi2b
Recurrent Platinum-Sensitive Ovarian Cancer Maintenance DolaflexinP1
Discovery
XMT-1660
B7-H4
Multiple Solid Tumors DolasynthenDiscovery
XMT-2056
HER2
Multiple Solid Tumors ImmunosynthenDiscovery
XMT-2068
Tumor-Associated Antigen
Undisclosed ImmunosynthenDiscovery
XMT-2175
Tumor-Associated Antigen
Undisclosed ImmunosynthenDiscovery
Multiple Programs
Undisclosed
Undisclosed Immunosynthen Dolasynthen Dolaflexin
Platform Collaborations
Multiple
Multiple
Undisclosed Dolasynthen
Multiple**
Multiple
Undisclosed DolaflexinDiscovery
ASN004
5T4
Undisclosed DolaflexinPreclinical
ADC Program Target Indication Platform Phase
upifitamab
rilsodotin (UpRi)*
NaPi2b Platinum-Resistant Ovarian Cancer Dolaflexin P2 Pivotal Study
upifitamab
rilsodotin (UpRi)*
NaPi2b Platinum-Resistant Ovarian Cancer Dolaflexin P1 Dose Escalation
upifitamab
rilsodotin (UpRi)*
NaPi2b Recurrent Platinum-Sensitive Ovarian Cancer Maintenance Dolaflexin P3
XMT-1592* NaPi2b Ovarian Cancer NSCLC Adenocarcinoma Dolasynthen P1 Dose Escalation
XMT-1660 B7-H4 Multiple Solid Tumors Dolasynthen Preclinical
XMT-2056 HER2 Undisclosed Immunosynthen Preclinical
XMT-2068 Tumor-Associated Antigen Undisclosed Immunosynthen Discovery
XMT-2175 Tumor-Associated Antigen Undisclosed Immunosynthen Discovery
Multiple Programs Undisclosed Undisclosed Immunosynthen Preclinical
Multiple Programs Undisclosed Undisclosed Immunosynthen Dolasynthen Dolaflexin Discovery
Multiple
Janssen Logo
Multiple Undisclosed Dolasynthen Discovery
Multiple
EMD Logo
Multiple** Undisclosed Dolaflexin P1 Dose Escalation
ASN004
Asana Logo
5T4 Undisclosed Dolaflexin P1 Dose Escalation

*NaPi2b antibody used in UpRi (formerly XMT-1536) is in-licensed from Recepta Biopharma. Recepta has rights to commercialize UpRi in Brazil.
**EMD Serono is an affiliate of Merck KGaA